Form 4: Zimmer Biomet CHRO's RSU Vesting and Tax Withholding

Lori Winkler, SVP and CHRO of Zimmer Biomet Holdings, Inc., reported the vesting of restricted stock units and subsequent share withholding for tax obligations.

Summary

• Lori Winkler, SVP and CHRO of Zimmer Biomet Holdings, Inc. (ZBH), reported transactions on November 28, 2025, related to her beneficial ownership.
• Winkler acquired 56.534 shares of common stock upon the vesting of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 56.534 shares of common stock were disposed of at $97.52 per share to satisfy FICA and related tax withholding obligations associated with the RSU award.
• An additional 122.695 shares of common stock were acquired upon the vesting of further RSUs at a price of $0.
• Another 122.695 shares of common stock were disposed of at $97.52 per share to cover tax withholding obligations for this RSU award.
• These dispositions were specifically to satisfy FICA and related taxes due to Winkler's retirement eligibility under the terms of the RSU awards.
• Following these reported transactions, Winkler directly beneficially owns 6,833 shares of Zimmer Biomet Holdings, Inc. common stock.
• Remaining RSUs include 1,699.466 units that are scheduled to vest on March 6, 2026.
• Additionally, 3,688.305 remaining RSUs are scheduled to vest, with 1,844.636 units vesting on February 20, 2026, and 1,843.669 units vesting on February 20, 2027.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction related to compensation, not indicative of company performance or strategic shifts.

Positives

• Vesting of Restricted Stock Units indicates a component of executive compensation is being realized, aligning management interests with shareholder value over time.

Negatives

• Shares were disposed of to cover tax withholding obligations, which is a standard practice upon RSU vesting and not indicative of a negative outlook.

Future Outlook

Remaining Restricted Stock Units held by Lori Winkler are scheduled to vest on March 6, 2026, February 20, 2026, and February 20, 2027, indicating future equity compensation realization.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation, which is a common practice across publicly traded companies in the medical technology and healthcare industry.

Stakeholder Impact

• Shareholders: The vesting and tax withholding of RSUs are routine compensation events that result in minor, expected dilution and are part of the company's established executive compensation structure.
• Employees: This filing demonstrates the company's executive compensation structure, which includes equity awards designed to incentivize long-term performance.

Next Steps

• Vesting of 1,699.466 remaining RSUs on March 6, 2026.
• Vesting of 1,844.636 remaining RSUs on February 20, 2026.
• Vesting of 1,843.669 remaining RSUs on February 20, 2027.

Key Dates

Keywords

Zimmer Biomet, ZBH, Form 4, insider transaction, RSU vesting, stock compensation, executive compensation, Lori Winkler